Panbela Therapeutics (PBLA) 10-Q 13 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 08, 2019
Document Information [Line Items]
Entity Registrant Name	Sun BioPharma, Inc.
Entity Central Index Key	0001029125
Trading Symbol	snbp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		6,631,308
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(g) Security	Common Stock, $0.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 3,377	$ 1,405
Prepaid expenses and other current assets	119	110
Income tax receivable	275	332
Total current assets	3,771	1,847
Other noncurrent assets	49	51
Total assets	3,820	1,898
Current liabilities:
Accounts payable	261	1,064
Accrued expenses	223	212
Convertible notes payable, net of debt discounts		64
Term debt, current portion	204	286
Accrued interest	1	4
Total current liabilities	689	1,630
Unsecured promissory note payable	742
Total liabilities	1,431	1,630
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2019 and December 31, 2018	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 6,624,166 and 5,077,483 shares issued and outstanding, as of September 30, 2019 and December 31, 2018, respectively	7	5
Additional paid-in capital	42,164	35,038
Accumulated deficit	(40,284)	(35,058)
Accumulated comprehensive income	502	283
Total stockholders' equity	2,389	268
Total liabilities and stockholders' equity	$ 3,820	$ 1,898

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,624,166	5,077,483
Common stock, shares outstanding (in shares)	6,624,166	5,077,483

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
General and administrative	$ 622	$ 467	$ 1,505	$ 1,779
Research and development	720	450	1,578	1,475
Operating loss	(1,342)	(917)	(3,083)	(3,254)
Other (expense) income:
Grant income		29		51
Interest expense	(3)	(3)	(2,187)	(1,763)
Other expense	(219)	(89)	(287)	(362)
Total other expense	(222)	(63)	(2,474)	(2,074)
Loss before income tax benefit	(1,564)	(980)	(5,557)	(5,328)
Income tax benefit	190	55	331	163
Net loss	(1,374)	(925)	(5,226)	(5,165)
Foreign currency translation adjustment	202	155	219	324
Comprehensive loss	$ (1,172)	$ (770)	$ (5,007)	$ (4,841)
Basic and diluted net loss per share (in dollars per share)	$ (0.23)	$ (0.18)	$ (0.97)	$ (1.14)
Weighted average shares outstanding - basic and diluted (in shares)	6,009,904	5,060,594	5,385,986	4,522,606

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	$ 25,625	$ (29,153)	$ (165)	$ (3,689)
Stock Issued During Period, Shares, New Issues	252
Sale of common stock and warrants		1,261			1,261
Stock-based compensation		1,792			1,792
Net loss			(1,753)		(1,753)
Foreign currency translation adjustment				69	69
Sale of common stock and warrants (in shares)	252
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	25,625	(29,153)	(165)	(3,689)
Net loss					(5,165)
Foreign currency translation adjustment					324
Warrants issued with sale of convertible notes payable
Common stock converted into convertible notes payable
Balances (in shares) at Sep. 30, 2018	5,061
Balances at Sep. 30, 2018	$ 5	33,612	(34,318)	159	(542)
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Stock Issued During Period, Shares, New Issues	216
Sale of common stock and warrants		1,080			1,080
Stock-based compensation		358			358
Net loss			(2,487)		(2,487)
Foreign currency translation adjustment				100	100
Beneficial conversion feature		121			121
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	751
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	3,257			3,258
Sale of common stock and warrants (in shares)	216
Balances (in shares) at Jun. 30, 2018	5,061
Balances at Jun. 30, 2018	$ 5	33,494	(33,393)	4	110
Stock-based compensation		146			146
Net loss			(925)		(925)
Foreign currency translation adjustment				155	155
Sale of common stock and warrants		(28)			(28)
Balances (in shares) at Sep. 30, 2018	5,061
Balances at Sep. 30, 2018	$ 5	33,612	(34,318)	159	(542)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Stock-based compensation		10			10
Net loss			(1,581)		(1,581)
Foreign currency translation adjustment				(32)	(32)
Beneficial conversion feature		353			353
Warrants issued with sale of convertible notes payable		419			419
Common stock converted into convertible notes payable (in shares)	(7)
Common stock converted into convertible notes payable		(25)			(25)
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Net loss					(5,226)
Foreign currency translation adjustment					219
Warrants issued with sale of convertible notes payable					419
Common stock converted into convertible notes payable					(25)
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	42,164	(40,284)	502	2,389
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Stock-based compensation		412			412
Net loss			(2,271)		(2,271)
Foreign currency translation adjustment				49	49
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	652
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	2,280			2,281
Balances (in shares) at Jun. 30, 2019	5,722
Balances at Jun. 30, 2019	$ 6	38,487	(38,910)	300	(117)
Stock Issued During Period, Shares, New Issues	902
Sale of common stock and warrants	$ 1	3,141			3,142
Stock-based compensation		536			536
Net loss			(1,374)		(1,374)
Foreign currency translation adjustment				202	202
Sale of common stock and warrants (in shares)	902
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	$ 42,164	$ (40,284)	$ 502	$ 2,389

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (5,226,000)	$ (5,165,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	958,000	1,202,000
Amortization of debt discount	2,061,000	1,687,000
Amortization of debt issuance costs	12,000	9,000
Non-cash interest expense	102,000	6,000
Changes in operating assets and liabilities:
Income tax receivable	44,000	(157,000)
Prepaid expenses and other current assets	(12,000)	23,000
Accounts payable	179,000	186,000
Accrued liabilities	15,000	(16,000)
Net cash used in operating activities	(1,867,000)	(2,225,000)
Cash flows from financing activities:
Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7	810,000
Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively	3,142,000	2,314,000
Repayment of demand note	(25,000)
Repayments of term debt	(82,000)
Net cash provided by financing activities	3,845,000	2,314,000
Effect of exchange rate changes on cash	(6,000)	(2,000)
Net change in cash	1,972,000	87,000
Cash at beginning of period	1,405,000	152,000
Cash at end of period	3,377,000	239,000
Supplemental disclosure of cash flow information:
Cash paid during period for interest	11,000	61,000
Supplemental disclosure of non-cash transactions:
Beneficial conversion feature on convertible notes	353,000	121,000
Warrants issued with convertible notes	419,000
Common stock converted into convertible notes payable	25,000
Conversion of convertible notes payable and accrued interest into common stock and warrants		2,908,000
Conversion of convertible notes payable and accrued interest into common stock	2,281,000	350,000
Issuance of unsecured promissory note in exchange for vendor accounts payable	742,000
Options granted in exchange for release from contingent payment obligations		$ 1,094,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Proceeds from the sale of convertible promissory notes, offering costs	$ 7
Proceeds from issuance of common stock and warrants, issuance costs	$ 16	$ 27

Note 1 - Business

Note 1 - Business	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Sun BioPharma, Inc. together with its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”), exists for the primary purpose of advancing the commercial development of a proprietary polyamine analogue (the “compound”) for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP- 101,

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $40.3 2011. nine September 30, 2019, $5.2 $2.1 $1.9 $3.1 $0.8 4 January 2019, December 2018 June 30, 2019. 101, September 30, 2019, $3.4 $3.1 $2.4 The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2018 March 22, 2019. 101 101 4

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2018 not 10 may not Recently Adopted Accounting Pronouncement s In June 2018, 2018 07, 718 2018 07 January 1, 2019. In February 2016, 2016 02, 842 12 not January 1, 2019. no no one

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan We will need to obtain additional funds to continue our operations and execute our current business plans. We may no not In closings occurring in August September 2019 902,067 $3.1 five $4.00. In closings occurring in December 2018 January 2019 $2.2 1,243,498 June 30, 2019 $105,000 651,758 $3.50. 6 five $4.50. If we are unable to obtain additional financing when needed, we believe that will need to reduce our operations by taking actions that may 101 third 101 Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP- 101 101 not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Beneficial c onversion f eature s For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt. Debt issuance costs Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt. Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the nine September 30, 2019 2018, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2019 2018 Employee and non-employee stock options 1,711,511 1,130,710 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 3,411,544 1,265,979 5,123,055 2,398,911

Note 6 - Indebtedness

Note 6 - Indebtedness	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Indebtedness Notes On June 30, 2019, $2.2 $105,000 $3.50 651,758 December 2018 January 2019 10.0% June 30, 2019. Term debt Effective April 5, 2019 May 1, 2019 December 31, 2019. 5,555 $4.50. five not $10,000. September 30, 2019 $204,000. Unsecured Promissory Notes On May 17, 2019 $742,000 not 1 December 31, 2020 2

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7 . Commitments and Contingencies License agreement Subsequent to the end of the quarter, on October 3, 2019, second No. A9672 101” second 101 101 ten first 101 December 31, 2025 may

Note 8 - Stockholders' Deficit

Note 8 - Stockholders' Deficit	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8 . S tock holders’ Deficit Shares of common stock reserved for future issuance were as follows as of September 3 0 , 2019: Total Reserved Stock options outstanding 1,711,511 Shares available for grant under equity incentive plan 52,849 Common shares issuable under outstanding common stock purchase warrants 3,411,544 5,175,904 Private Placement During the quarter ended September 30, 2019, 902,067 2019 $3.1 4,

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9 . S tock -based Compensation 2016 The Sun BioPharma, Inc. 2016 “2016 March 2016 May 2016. 2016 2016 no 2016 ten 2016 1,500,000 September 30, 2019, 1,447,151 2016 52,849 2011 Our Board of Directors ceased making awards under the Sun BioPharma, Inc. 2011 “2011 2016 2011 2011 ten zero two September 30, 2019, 264,360 2011 Stock -based Compensation Expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2019 $0.6 September 30, 2019 eleven Stock-based compensation expense for each of the periods presented is as follows (in thousands): Nine Months Ended September 30, 2019 2018 General and Administrative $ 573 $ 1,404 Research and Development 385 892 $ 958 $ 2,296 A summary of stock option activity for the nine September 30, 2019 Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at December 31, 2018 732,149 1,032,211 $ 8.90 $ 169,495 Granted (700,100 ) 700,100 3.41 Exercised - - - Cancelled - - - Forfeitures 20,800 (20,800 ) 15.10 Balance at September 30, 2019 52,849 1,711,511 $ 6.58 $ 1,674,675 Information about stock options outstanding, vested and expected to vest as of September 30, 2019, Outstanding, Vested and Expected to Vest Options Vested and Excercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Excercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 3.25 $ 1.029 26,360 3.25 $2.275 - $2.50 38,000 4.37 $ 2.464 38,000 4.37 $2.95 - $3.175 740,800 8.50 $ 3.011 398,125 7.52 $4.50 - $8.10 538,300 8.04 $ 6.742 506,500 8.18 $10.00 - $10.10 54,000 7.80 $ 10.007 54,000 7.80 $15.10 314,051 6.66 $ 15.100 307,051 6.76 Totals 1,711,511 7.88 $ 6.581 1,330,036 7.43 Key assumptions The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three September 30, 2019: 2019 Common stock fair value 4.50 - 5.00 Risk-free interest rate 1.55% - 1.57% Expected dividend yield 0% Expected Option life (years) 5.0 - 5.5 Expected stock price volatility 72%

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
Beneficial Conversion Feature, Policy [Policy Text Block]	Beneficial c onversion f eature s For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.
Debt Issuance Costs [Policy Text Block]	Debt issuance costs Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-based Payment Arrangement [Policy Text Block]	Stock In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the nine September 30, 2019 2018,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2019 2018 Employee and non-employee stock options 1,711,511 1,130,710 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 3,411,544 1,265,979 5,123,055 2,398,911

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2019 2018 Employee and non-employee stock options 1,711,511 1,130,710 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 3,411,544 1,265,979 5,123,055 2,398,911

Note 8 - Stockholders' Deficit

Note 8 - Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Total Reserved Stock options outstanding 1,711,511 Shares available for grant under equity incentive plan 52,849 Common shares issuable under outstanding common stock purchase warrants 3,411,544 5,175,904

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Nine Months Ended September 30, 2019 2018 General and Administrative $ 573 $ 1,404 Research and Development 385 892 $ 958 $ 2,296
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at December 31, 2018 732,149 1,032,211 $ 8.90 $ 169,495 Granted (700,100 ) 700,100 3.41 Exercised - - - Cancelled - - - Forfeitures 20,800 (20,800 ) 15.10 Balance at September 30, 2019 52,849 1,711,511 $ 6.58 $ 1,674,675
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Excercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Excercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 3.25 $ 1.029 26,360 3.25 $2.275 - $2.50 38,000 4.37 $ 2.464 38,000 4.37 $2.95 - $3.175 740,800 8.50 $ 3.011 398,125 7.52 $4.50 - $8.10 538,300 8.04 $ 6.742 506,500 8.18 $10.00 - $10.10 54,000 7.80 $ 10.007 54,000 7.80 $15.10 314,051 6.66 $ 15.100 307,051 6.76 Totals 1,711,511 7.88 $ 6.581 1,330,036 7.43
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2019 Common stock fair value 4.50 - 5.00 Risk-free interest rate 1.55% - 1.57% Expected dividend yield 0% Expected Option life (years) 5.0 - 5.5 Expected stock price volatility 72%

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		105 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (1,374)	$ (2,271)	$ (1,581)	$ (925)	$ (2,487)	$ (1,753)	$ (5,226)	$ (5,165)	$ (40,300)
Amortization of Debt Discount (Premium)							2,061	1,687
Net Cash Provided by (Used in) Operating Activities, Total							(1,867)	(2,225)
Proceeds from Issuance of Private Placement							3,142	2,314
Proceeds from Issuance or Sale of Equity, Total							800
Cash and Cash Equivalents, at Carrying Value, Ending Balance	3,377			239			3,377	239	3,377	$ 1,405	$ 152
Working Capital	3,100						3,100		3,100
Stockholders' Equity Attributable to Parent, Ending Balance	$ 2,389	$ (117)	$ (588)	$ (542)	$ 110	$ (2,320)	$ 2,389	$ (542)	$ 2,389	$ 268	$ (3,689)

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($)	Jun. 30, 2019	Sep. 30, 2019	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Private Placement					$ 3,142,000	$ 2,314,000
Proceeds from Convertible Debt					$ 810,000
Conversion from Debt to Common Stock [Member]
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Conversion, Converted Instrument, Shares Issued	651,758
Debt Instrument, Convertible, Conversion Price	$ 3.50
Unsecured Convertible Promissory Notes [Member]
Proceeds from Convertible Debt			$ 2,200,000
Warrants in Connection with the Private Placement [Member]
Warrants and Rights Outstanding, Term		5 years		5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4		$ 4	$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		902,067		902,067	902,067
Warrants In Connection with 2018 Convertible Notes Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,243,498
Warrants in Connection with Securities Purchase Agreement [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.50
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		902,067		902,067
Proceeds from Issuance of Private Placement		$ 3,100,000		$ 3,100,000

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%

Note 5 - Summary of Significa_4

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Anti-dilutive securities (in shares)	5,123,055	2,398,911
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	1,711,511	1,130,710
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		2,222
Warrant [Member]
Anti-dilutive securities (in shares)	3,411,544	1,265,979

Note 6 - Indebtedness (Details

Note 6 - Indebtedness (Details Textual) - USD ($)	Jun. 30, 2019	May 17, 2019	Apr. 05, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Increase (Decrease) in Accounts Payable, Total		$ 742,000		$ 179,000	$ 186,000
Unsecured Long-term Debt, Noncurrent				742,000
Warrants In Connection with Term Debt [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,555
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.50
Warrants and Rights Outstanding, Term			5 years
Term Debt [Member]
Debt Instrument, Periodic Payment, Total			$ 10,000
Long-term Debt, Total				$ 204,000
Unsecured Promissory Note [Member]
Unsecured Long-term Debt, Noncurrent		$ 742,000
Convertible Debt [Member] | The 2018 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Conversion from Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 2,200,000
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Instrument, Convertible, Conversion Price	$ 3.50
Debt Conversion, Converted Instrument, Shares Issued	651,758

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual)	Dec. 22, 2011
Licensing Agreement with University of Florida Research Foundation [Member]
Royalty Term	10 years

Note 8 - Stockholders' Defici_2

Note 8 - Stockholders' Deficit (Details Textual) - USD ($)	2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Private Placement			$ 3,142,000	$ 2,314,000
Warrants in Connection with the Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	902,067	902,067	902,067
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	902,067	902,067
Proceeds from Issuance of Private Placement	$ 3,100,000	$ 3,100,000

Note 8 - Stockholders' Defici_3

Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2019	Dec. 31, 2018
Stock options outstanding (in shares)	1,711,511
Shares available for grant under equity incentive plan (in shares)	52,849	732,149
Common shares issuable under outstanding common stock purchase warrants (in shares)	3,411,544
(in shares)	5,175,904

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions	May 31, 2016	Sep. 30, 2019	Dec. 31, 2018
Common Stock, Capital Shares Reserved for Future Issuance		5,175,904
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,711,511	1,032,211
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 0.6
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		2 years 270 days
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,447,151
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,500,000	52,849
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		264,360
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		0 years
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based compensation expense	$ 958	$ 2,296
General and Administrative Expense [Member]
Share-based compensation expense	573	1,404
Research and Development Expense [Member]
Share-based compensation expense	$ 385	$ 892

Note 9 - Stock-based Compensa_5

Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Balance, shares available for grant (in shares)	732,149
Balance, shares underlying options (in shares)	1,032,211
Balance, weighted average exercise price per share (in dollars per share)	$ 6.58	$ 8.90
Aggregate intrinsic value	$ 1,674,675	$ 169,495
Granted, shares available for grant (in shares)	(700,100)
Granted, shares underlying options (in shares)	700,100
Granted, weighted average exercise price per share (in dollars per share)	$ 3.41
Forfeitures , shares available for grant (in shares)	20,800
Forfeited, shares underlying options (in shares)	(20,800)
Forfeited, weighted average exercise price per share (in dollars per share)	$ 15.10
Balance, shares available for grant (in shares)	52,849
Balance, shares underlying options (in shares)	1,711,511

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Options outstanding (in shares) | shares	1,711,511
Options outstanding, weighted average remaining contractual life (Year)	7 years 321 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.581
Options excercisable (in shares) | shares	1,330,036
Options excercisable, weighted average remaining contractual life (Year)	7 years 156 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	26,360
Options outstanding, weighted average remaining contractual life (Year)	3 years 91 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.029
Options excercisable (in shares) | shares	26,360
Options excercisable, weighted average remaining contractual life (Year)	3 years 91 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.275
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	38,000
Options outstanding, weighted average remaining contractual life (Year)	4 years 135 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.464
Options excercisable (in shares) | shares	38,000
Options excercisable, weighted average remaining contractual life (Year)	4 years 135 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 3.175
Options outstanding (in shares) | shares	740,800
Options outstanding, weighted average remaining contractual life (Year)	8 years 182 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.011
Options excercisable (in shares) | shares	398,125
Options excercisable, weighted average remaining contractual life (Year)	7 years 189 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	538,300
Options outstanding, weighted average remaining contractual life (Year)	8 years 14 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.742
Options excercisable (in shares) | shares	506,500
Options excercisable, weighted average remaining contractual life (Year)	8 years 65 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 10
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	54,000
Options outstanding, weighted average remaining contractual life (Year)	7 years 292 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 10.007
Options excercisable (in shares) | shares	54,000
Options excercisable, weighted average remaining contractual life (Year)	7 years 292 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) | shares	314,051
Options outstanding, weighted average remaining contractual life (Year)	6 years 240 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options excercisable (in shares) | shares	307,051
Options excercisable, weighted average remaining contractual life (Year)	6 years 277 days

Note 9 - Stock-based Compensa_7

Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2019$ / shares	Sep. 30, 2019$ / shares
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	72.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 4.50	$ 4.50
Risk-free interest rate	1.55%
Expected Option life (years) (Year)	5 years
Maximum [Member]
Common stock fair value (in dollars per share)	$ 5	$ 5
Risk-free interest rate	1.57%
Expected Option life (years) (Year)	5 years 182 days